Get the Stockscreener App
1.54
0.65%
-0.01
Pre-market:
1.60
0.06
+3.90%
Alx Oncology Holdings Inc stock is traded at $1.54, with a volume of 99,268.
It is down -0.65% in the last 24 hours and down -15.85% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.55
Open:
$1.52
24h Volume:
99,268
Relative Volume:
0.11
Market Cap:
$82.47M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.5185
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-12.00%
1M Performance:
-15.85%
6M Performance:
+185.19%
1Y Performance:
+7.69%
1-Day Range:
$1.49
$1.55
1-Week Range:
$1.49
$1.77
52-Week Range:
$0.404
$2.27
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.54 | 83.00M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
Is ALX Oncology Holdings Inc. stock attractive for hedge fundsSell Signal & Technical Pattern Recognition Alerts - newser.com
Will ALX Oncology Holdings Inc. continue its uptrend2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
Analyzing recovery setups for ALX Oncology Holdings Inc. investorsJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Can ALX Oncology Holdings Inc. stock attract ESG capital inflowsIPO Watch & Short-Term Swing Trade Alerts - newser.com
Statistical indicators supporting ALX Oncology Holdings Inc.’s strengthShort Setup & Real-Time Market Trend Scan - newser.com
Will ALX Oncology Holdings Inc. stock reach Wall Street targetsJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com
Can ALX Oncology Holdings Inc. hit a new high this month2025 Price Targets & Real-Time Price Movement Reports - newser.com
How to build a dashboard for ALX Oncology Holdings Inc. stockWeekly Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Will ALX Oncology Holdings Inc. outperform the marketWeekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Will ALX Oncology Holdings Inc. benefit from macro trendsChart Signals & High Win Rate Trade Alerts - newser.com
Is ALX Oncology Holdings Inc. stock a buy before product launches2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
Visual analytics tools that track ALX Oncology Holdings Inc. performanceRecession Risk & AI Optimized Trade Strategies - newser.com
Analyzing ALX Oncology Holdings Inc. with risk reward ratio charts2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Building trade automation scripts for ALX Oncology Holdings Inc.Trade Entry Report & Consistent Profit Alerts - newser.com
ALX Oncology (ALXO) Expected to Announce Earnings on Thursday - MarketBeat
Key metrics from ALX Oncology Holdings Inc.’s quarterly dataWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
ALX Oncology (NASDAQ: ALXO) to review biomarker data at SITC, report Q3 2025 results - Stock Titan
Will ALX Oncology Holdings Inc. stock benefit from automation2025 Trade Ideas & Reliable Intraday Trade Alerts - newser.com
Is ALX Oncology Holdings Inc. stock attractive for long term wealth building2025 Performance Recap & Real-Time Buy Signal Notifications - newser.com
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):